OLR1 and prostate cancer: Considering this, high concentrations of circulating LDL in obese patients with prostate cancer could contribute to tumor progression through LOX-1 activation by oxidation modified LDL (oxLDL) generated in the oxidant microenvironment, present in the prostate tumor stroma.